Clinical & Experimental Metastasis最新文献_第6页

The clinical trial landscape of colorectal cancer liver metastases: profile analysis and target prediction. 结直肠癌肝转移的临床试验前景：概况分析和目标预测。

IF 3.7 3区医学

Clinical & Experimental Metastasis Pub Date : 2026-01-19 DOI: 10.1007/s10585-026-10392-3

Ming Li, Jinyan Kai, Yuchentian Xu, Shuai Zhu, Zhijun Chen, Huiqing Zhao, Weixiong Zhu

{"title":"The clinical trial landscape of colorectal cancer liver metastases: profile analysis and target prediction.","authors":"Ming Li, Jinyan Kai, Yuchentian Xu, Shuai Zhu, Zhijun Chen, Huiqing Zhao, Weixiong Zhu","doi":"10.1007/s10585-026-10392-3","DOIUrl":"10.1007/s10585-026-10392-3","url":null,"abstract":"By conducting colorectal cancer liver metastases (CRLM) clinical trials and analyzing treatment and prognostic targets, to provide clinical trial references for CRLM. We analyzed global and Chinese CRLM clinical trials from the Informa database, focusing on fruquintinib, sintilimab, and dual immunotherapy (CTLA-4 + PD-1). The study evaluated oncogenic biomarkers and therapeutic targets, assessing their safety by integrating data from Genotype-Tissue Expression (GTEx)-RNA, Human Protein Atlas (HPA)-RNA and HPA-Protein. Target specificity and future potential were further investigated using Clinical Proteomic Tumor Analysis Consortium (CPTAC) datasets and HPA pathology. CRLM clinical trials numbers have stabilized, focusing mainly on combination therapies, with China and the US leading in trial numbers. Single-agent trials emphasize targeted therapy, while chemo plus targeted therapy dominates combinations, reflecting a treatment model based on chemotherapy with targeted therapy breakthroughs. Chinese independently developed drugs-fruquintinib and sintilimab-and dual immunotherapy (CTLA-4 + PD-1) are still emerging, with fruquintinib used for CRLM resistant to multi-line chemo and anti-VEGF. The relevance of VEGFA and EGFR targets highlights targeted therapy's importance and supports drugs like fruquintinib. Targets analysis shows most have low safety and specificity, but CD34, FLT1, and TP53 exhibit good profiles and potential for CRLM therapy and prognosis. This study, by integrating and analyzing the clinical trial data related to CRLM, aims to conduct an in-depth investigation and evaluate the safety specificity of the treatment targets through reference.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 1","pages":"10"},"PeriodicalIF":3.7,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digital spatial profiling identifies features of primary and locoregional metastatic vasculature in triple negative breast cancer. 数字空间分析识别三阴性乳腺癌原发性和局部转移性血管的特征。

IF 3.7 3区医学

Clinical & Experimental Metastasis Pub Date : 2026-01-19 DOI: 10.1007/s10585-026-10391-4

Akhilandeshwari Ravichandran, Kyle Upton, Shiva Taheri, Cheng Liu, Kaltin Ferguson, Mark Adams, Laura J Bray

{"title":"Digital spatial profiling identifies features of primary and locoregional metastatic vasculature in triple negative breast cancer.","authors":"Akhilandeshwari Ravichandran, Kyle Upton, Shiva Taheri, Cheng Liu, Kaltin Ferguson, Mark Adams, Laura J Bray","doi":"10.1007/s10585-026-10391-4","DOIUrl":"10.1007/s10585-026-10391-4","url":null,"abstract":"Triple Negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer with limited treatment options and poor prognosis. Coupled with this, TNBC shows a high rate of metastasis which is known to be aided by tumour vasculature. Endothelial cells that form the lining of the tumour vasculature exhibit distinct genotype and phenotype differences compared with normal tissue vasculature. However, little is known about endothelial signatures that drive metastasis from a primary tumour, particularly in the context of immune infiltration. In this study, we utilized GeoMX Digital Spatial Profiling to investigate spatial proteomics differences in endothelial cells between primary and secondary sites of TNBC. By segmenting tissues using epithelial (PanCK), immune (CD45), and endothelial (CD31) markers, we analysed the microvasculature for a panel of 79 target proteins. In paired primary and secondary TNBC tissues, we identified significant downregulation of fibronectin (- log2(Fold-Change) = - 1.7, p < 0.001) in secondary sites. Specifically in epithelial regions, S100B was found to be downregulated in secondary microvasculature when compared to primary tumours. Additionally, metastasis-free primary tissues exhibited upregulated expression of S100B when compared to primary tissues that metastasized. Our study highlights the potential contributions of microvasculature to metastatic progression in TNBC, presenting new opportunities to explore them as potential biomarkers of TNBC metastasis.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 1","pages":"11"},"PeriodicalIF":3.7,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What we can learn from the lepidic growth pattern of pulmonary metastases. 我们可以从肺转移瘤的缓慢生长模式中学到什么？

IF 3.7 3区医学

Clinical & Experimental Metastasis Pub Date : 2026-01-12 DOI: 10.1007/s10585-025-10390-x

Alberto Ficarelli, Carolina Sassorossi, Filippo Lococo, Andrea Galli

引用次数: 0

Breast cancer liver metastases and the impact of receptor expression on survival. 乳腺癌肝转移及受体表达对生存的影响。

IF 3.7 3区医学

Clinical & Experimental Metastasis Pub Date : 2026-01-09 DOI: 10.1007/s10585-025-10387-6

Ellen Hansson, Marcus Sundén, Charlotta Wadsten, Gunilla Rask, Anne Andersson, Malin Sund, Oskar Hemmingsson

{"title":"Breast cancer liver metastases and the impact of receptor expression on survival.","authors":"Ellen Hansson, Marcus Sundén, Charlotta Wadsten, Gunilla Rask, Anne Andersson, Malin Sund, Oskar Hemmingsson","doi":"10.1007/s10585-025-10387-6","DOIUrl":"10.1007/s10585-025-10387-6","url":null,"abstract":"The aim was to determine the frequency of altered receptor expression between primary breast cancer and liver metastases, and to examine the impact of receptor expression on survival. The conversion frequency of estrogen- (ER), progesterone- (PgR) and human epidermal growth factor receptor 2 (HER2) was investigated. The prognostic value of the receptor status in the primary tumor versus the metastases was estimated. Data on a population-based regional cohort of 7292 breast cancer patients from 2009 to 2018 were collected from the National Breast Cancer Register. Biomarker expression and intrinsic subtype was studied among those who developed liver metastases with available histopathological records. The study included 311 patients with liver metastases. Conversion of ER, PgR and HER2 occurred in 16%, 47% and 12% of patients, respectively. The subtype converted in 26%. HER2 amplification in the primary tumor or metastases was associated with improved survival. Positive ER and PgR in breast cancer and positive ER in liver metastases were beneficial for survival. A combined primary tumor and metastasis receptor evaluation had the highest prognostic value. Receptor conversion from primary tumor to liver metastases is common. HER2 amplification and positive ER or PgR are associated with improved survival. Accordingly, luminal HER2 positive tumors have improved survival compared to other intrinsic subtypes. To personalize treatment for each patient, a liver biopsy is warranted at diagnosis of breast cancer liver metastases.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 1","pages":"8"},"PeriodicalIF":3.7,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12789201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predictive significance of anterior and posterior minimal extrathyroidal extension for central lymph node metastasis in cN0 papillary thyroid carcinoma. 前、后最小甲状腺外展对cN0型甲状腺乳头状癌中央淋巴结转移的预测意义。

IF 3.7 3区医学

Clinical & Experimental Metastasis Pub Date : 2026-01-09 DOI: 10.1007/s10585-025-10388-5

Qi Zhao, Yuyang Zhang, Rui Hua, Bin Lv, Nan Liu

{"title":"Predictive significance of anterior and posterior minimal extrathyroidal extension for central lymph node metastasis in cN0 papillary thyroid carcinoma.","authors":"Qi Zhao, Yuyang Zhang, Rui Hua, Bin Lv, Nan Liu","doi":"10.1007/s10585-025-10388-5","DOIUrl":"10.1007/s10585-025-10388-5","url":null,"abstract":"The specific role of minimal extrathyroidal extension (mETE)-particularly the differences between anterior mETE (ant-mETE) and posterior mETE (post-mETE)-in relation to Central lymph node metastasis (CLNM) for papillary thyroid carcinoma (PTC) remains uncertain. This study aimed to examine the effects of ant-mETE and post-mETE on CLNM and to construct a preoperative risk-stratification nomogram for CLNM to guide central lymph node dissection (CLND). This retrospective study analyzed 1694 consecutive clinically node-negative (cN0) PTC cases treated between 2017 and 2024. Univariate and multivariate analyses were performed to identify clinicopathological predictors of CLNM. Subsequently, a predictive nomogram incorporating significant variables was developed and internally validated. Among 1694 cN0 PTC cases analyzed, 833 (49.2%) demonstrated pathologic CLNM, and post-mETE was significantly associated with higher CLNM rates compared to ant-mETE (p < 0.001). Multivariable analysis identified seven independent CLNM predictors: age > 55 years (OR 0.466), male gender (OR 2.479), tumor size > 1 cm (OR 3.290), bilateral involvement (OR 1.335), multifocality (OR 1.420), lower pole location (OR 1.710), and mETE presence (ant-mETE OR = 2.47, post-mETE OR = 3.492). The developed nomogram demonstrated excellent discriminative ability (AUC = 0.774) and clinical utility. Both ant-mETE and post-mETE were independently associated with CLNM, with post-mETE demonstrating significantly higher metastatic propensity. The predictive nomogram developed in this study demonstrated moderate discriminative accuracy for CLNM, which could help identify occult metastases, thereby facilitating prophylactic CLND and reducing reoperation rates in patients.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 1","pages":"6"},"PeriodicalIF":3.7,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

KIF14 in cancer biology: implications for diagnosis and therapy. 癌症生物学中的KIF14：诊断和治疗的意义。

IF 3.7 3区医学

Clinical & Experimental Metastasis Pub Date : 2026-01-09 DOI: 10.1007/s10585-025-10389-4

Ashok Kumar Bishoyi, Shaker Al-Hasnaawei, Subbulakshmi Ganesan, Aman Shankhyan, Anima Nanda, Aashna Sinha, Subhashree Ray, Deepak Nathiya

{"title":"KIF14 in cancer biology: implications for diagnosis and therapy.","authors":"Ashok Kumar Bishoyi, Shaker Al-Hasnaawei, Subbulakshmi Ganesan, Aman Shankhyan, Anima Nanda, Aashna Sinha, Subhashree Ray, Deepak Nathiya","doi":"10.1007/s10585-025-10389-4","DOIUrl":"10.1007/s10585-025-10389-4","url":null,"abstract":"Kinesin family member 14 (KIF14), a microtubule-associated motor protein, plays a crucial role in cytoskeletal dynamics, intracellular transport, and cell division. Oncological studies have consistently reported KIF14 overexpression across various cancers, including breast, ovarian, lung, liver, and brain tumors, associating it with poor clinical outcomes, increased tumor aggressiveness, and resistance to conventional therapies. This review comprehensively analyzed the involvement of KIF14 in cancer progression, particularly its roles in cell cycle regulation, mitotic spindle formation, and oncogenic signaling pathways. Additionally, the molecular mechanisms underlying its tumorigenic effects, its potential as a prognostic biomarker, and its viability as a therapeutic target are explored. The expanding understanding of KIF14's oncogenic functions present promising opportunities for developing novel therapeutic strategies aimed at this key regulator of tumor growth and metastasis, addressing the urgent need for treatments targeting aggressive and therapy-resistant malignancies.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 1","pages":"7"},"PeriodicalIF":3.7,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145942724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of neoadjuvant cetuximab on liver function and tumor reduction in a murine model of selective portal vein ligation. 新辅助西妥昔单抗对小鼠选择性门静脉结扎模型肝功能和肿瘤减少的影响。

IF 3.7 3区医学

Clinical & Experimental Metastasis Pub Date : 2025-12-27 DOI: 10.1007/s10585-025-10386-7

Guillermo Tirado-Rodríguez, Inmaculada Ruiz-Montesinos, Sira Iturrizaga, Amador García Ruiz de Gordejuela, Paula Aizpiolea, Daniel Alonso-Alconada, Ignacio García-Alonso, Borja Herrero de la Parte

{"title":"Impact of neoadjuvant cetuximab on liver function and tumor reduction in a murine model of selective portal vein ligation.","authors":"Guillermo Tirado-Rodríguez, Inmaculada Ruiz-Montesinos, Sira Iturrizaga, Amador García Ruiz de Gordejuela, Paula Aizpiolea, Daniel Alonso-Alconada, Ignacio García-Alonso, Borja Herrero de la Parte","doi":"10.1007/s10585-025-10386-7","DOIUrl":"10.1007/s10585-025-10386-7","url":null,"abstract":"Colorectal cancer mortality is largely driven by metastatic spread, with colorectal liver metastases (CRLM) being the most frequent. Treatment often combines surgery and systemic therapy, including anti-EGFR agents such as cetuximab. This study evaluated the cytoreductive effect of cetuximab on CRLM and its influence on liver function and regeneration in a selective portal vein ligation (PVL) model. Sixty-six male WAG/RijHsd rats were used. Seven days before PVL, twelve tumor-bearing animals received intra-arterial cetuximab, while other six received vehicle (saline). Additional groups included tumor-bearing rats without PVL, rats undergoing PVL alone, and untreated controls (n = 6 each). Seven days after PVL, the future remnant liver volume (%FRL) and hepatocyte replication were quantified. Serum markers for hepatic, renal, and systemic injury were analyzed, and tumor volume was assessed by ultrasound before and after PVL. The regenerative response following PVL was not significantly affected by cetuximab, with %FRL reaching 80-90%. However, hepatocyte nuclei exhibited a smaller mean area compared with non-treated animals (45.35 ± 9.09 vs. 43.54 ± 9.87 μm²; p < 0.001). Liver function remained preserved, although glucose levels decreased after PVL. Cetuximab significantly reduced tumor growth driven by hepatic regeneration (1.12 ± 0.45 vs. 0.53 ± 0.16 mL; p < 0.01). Neoadjuvant intra-arterial cetuximab does not impair liver regeneration after PVL while effectively limiting tumor proliferation linked to regenerative stimuli. These findings support its perioperative safety and potential use to prevent tumor recurrence in patients with CRLM undergoing staged hepatectomy.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 1","pages":"5"},"PeriodicalIF":3.7,"publicationDate":"2025-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12743101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145843163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PRL-3 as a metastasis-associated phosphatase in colorectal cancer: Mechanisms and therapeutic strategies. PRL-3作为结直肠癌转移相关磷酸酶：机制和治疗策略

IF 3.7 3区医学

Clinical & Experimental Metastasis Pub Date : 2025-12-04 DOI: 10.1007/s10585-025-10385-8

Sarah J Greenstein, Charmaine A Ramlogan-Steel, Ingrid A Wise, Rebecca J Wilson, Jason C Steel

{"title":"PRL-3 as a metastasis-associated phosphatase in colorectal cancer: Mechanisms and therapeutic strategies.","authors":"Sarah J Greenstein, Charmaine A Ramlogan-Steel, Ingrid A Wise, Rebecca J Wilson, Jason C Steel","doi":"10.1007/s10585-025-10385-8","DOIUrl":"10.1007/s10585-025-10385-8","url":null,"abstract":"Metastasis remains the leading cause of mortality in colorectal cancer (CRC), and understanding the molecular drivers of this process is central to developing improved interventions. Phosphatase of regenerating liver-3 (PRL-3; PTP4A3) has emerged as a metastasis-associated phosphatase with selective expression in advanced CRC and nearly universal presence in liver metastases. Structurally, PRL-3 is a dual-specificity phosphatase with a conserved catalytic domain and a C-terminal prenylation motif that directs it to cellular membranes. Functionally, PRL-3 disrupts polarity, remodels the cytoskeleton, and interacts with magnesium transporters to influence ion homeostasis. In malignancy, it integrates into the signaling pathways of epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), mitogen-activated protein kinase (MAPK), and nuclear factor kappa-light-chain-enhancer of activated b cells/interleukin-6/signal transducer and activator of transcription 3 (NF-κB/IL-6/STAT3). This integration promotes epithelial–mesenchymal transition, matrix degradation, survival in the circulation, colonization of distant organs, angiogenesis, and immune evasion. Clinically, high PRL-3 expression correlates with advanced disease staging, recurrence, and poor survival, underscoring its prognostic value. Therapeutic strategies targeting PRL-3—including small-molecule allosteric inhibitors, RNA interference, CRISPR-based editing, and the first-in-class antibody PRL3-zumab—demonstrate promising preclinical activity, with early clinical translation underway. This review highlights PRL-3 as a structural, functional, and translationally relevant driver of metastasis and considers its potential as a biomarker and therapeutic target in CRC and beyond.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 1","pages":"4"},"PeriodicalIF":3.7,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145667216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of incidental low-dose radiation on abscopal responses after stereotactic body radiotherapy in patients with metastatic cancer: a retrospective real-world analysis. 偶发低剂量辐射对转移性癌症患者立体定向放射治疗后体外反应的影响：一项回顾性现实世界分析。

IF 3.7 3区医学

Clinical & Experimental Metastasis Pub Date : 2025-11-27 DOI: 10.1007/s10585-025-10381-y

Jae Sik Kim, Jun Yeong Song, Bum-Sup Jang, Byoung Hyuck Kim

{"title":"Effects of incidental low-dose radiation on abscopal responses after stereotactic body radiotherapy in patients with metastatic cancer: a retrospective real-world analysis.","authors":"Jae Sik Kim, Jun Yeong Song, Bum-Sup Jang, Byoung Hyuck Kim","doi":"10.1007/s10585-025-10381-y","DOIUrl":"10.1007/s10585-025-10381-y","url":null,"abstract":"Although the abscopal effect is a rare phenomenon, preclinical and clinical studies have suggested that low-dose radiation may modulate the tumor microenvironment and enhance immune activation. We investigated the effect of incidental low-dose radiation on abscopal responses in patients with metastatic cancer treated with stereotactic body radiotherapy (SBRT). We retrospectively analyzed 39 patients with metastatic cancer who underwent SBRT for a single lesion with additional non-target lesions and received incidental low-dose radiation between 2010 and 2022. Tumor responses in these non-target lesions were evaluated within 3 months of SBRT and predictors of the abscopal effect were explored. At a median follow-up of 13.9 months, patients experiencing the abscopal effect (23.1%) showed significantly improved 1-year progression-free survival compared to those without it, while the 1-year overall survival showed a favorable trend without statistical significance. Among the 79 non-target lesions, those receiving incidental very low-dose radiation (< 0.5 Gy) demonstrated a significantly higher likelihood of an abscopal response than those receiving no radiation (odds ratio [OR] 9.707, p = 0.041). Higher pre-SBRT lymphocyte counts (> 2,000/μL) were also associated with an increased abscopal response (OR 7.782, p = 0.048). Conversely, pre-SBRT systemic therapy was inversely associated with abscopal response (OR 0.182, p = 0.034). Unintended low-dose radiation may exert an abscopal effect in patients with metastatic cancer treated with SBRT. This effect was linked to improved progression-free survival, indicating a possible clinical benefit. Further studies are required to confirm these results, which may inform SBRT planning strategies.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 1","pages":"3"},"PeriodicalIF":3.7,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145630767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Importance of the timing of combined electrochemotherapy and immunotherapy in the treatment of advanced melanoma. 化疗联合免疫治疗在晚期黑色素瘤治疗中的重要性。

IF 3.7 3区医学

Clinical & Experimental Metastasis Pub Date : 2025-11-21 DOI: 10.1007/s10585-025-10384-9

Erika Gabriella Kis, Matteo Brizio, Giuseppe Riva, Barbara Peric, Joy Odili, Matteo Mascherini, Francesco Russano, Giulia Giorgione, Paolo Matteucci, Siva Kumar, Francesca Tauceri, Hadrian Nassabi, Silvia Carpenè, Giulia Colavitti, Christian Kunte, Giulia Bertino, Veronica Seccia, Francesca de Terlizzi, Gregor Sersa

{"title":"Importance of the timing of combined electrochemotherapy and immunotherapy in the treatment of advanced melanoma.","authors":"Erika Gabriella Kis, Matteo Brizio, Giuseppe Riva, Barbara Peric, Joy Odili, Matteo Mascherini, Francesco Russano, Giulia Giorgione, Paolo Matteucci, Siva Kumar, Francesca Tauceri, Hadrian Nassabi, Silvia Carpenè, Giulia Colavitti, Christian Kunte, Giulia Bertino, Veronica Seccia, Francesca de Terlizzi, Gregor Sersa","doi":"10.1007/s10585-025-10384-9","DOIUrl":"10.1007/s10585-025-10384-9","url":null,"abstract":"Published data on the combination of immunotherapy and electrochemotherapy (ECT) consistently indicate a benefit in tumor response, but an important question, the optimal timing for combination, remains unclear. We investigated the impact of the timing of the ECT/immunotherapy combination. A cohort of 170 stage IIIC–IV melanoma patients from the Insp-ECT registry were evaluated for toxicity and local, systemic and long-term responses after combined ECT/immunotherapy treatment. Three groups were compared: patients who received immunotherapy before, during and after ECT. Combined treatment with ECT did not increase the toxicity profile of ECT. The best response was achieved with concomitant treatment with ECT. After 2 months, the local response was 61% CR and 20% PR, the systemic response was 27% CR and 17% PR, and the RFS was 87% after 12 months and 66% after 24 months. All groups had poorer results if compared with concomitant combined treatment, and when immunotherapy was given before ECT, a significantly worse response was detected. This study shows that the best time for ECT is during immunotherapy with immune checkpoint inhibitors. Our study indicates that ECT could be associated with increased benefits of immunotherapies, potentially influencing the response rate of melanoma patients to immunotherapy.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 1","pages":"2"},"PeriodicalIF":3.7,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0